Skip to main content

Table 4 Association of 10 IR-associated peripheral blood DNA methylation markers with neurological traits in ROSMAP

From: Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer’s disease at CPT1A locus

CpG marker

Closest Gene (bp distance)

Clinical diagnosis of cognitive status at time of death

Braak stage

CERAD score

B

SE

P

B

SE

P

B

SE

P

cg17901584

DHCR24 (785)

− 0.0006

0.0009

0.50

0.0006

0.0012

0.60

0.0014

0.0012

0.25

cg15150970

DNMT3A (0)

0.0008

0.0007

0.25

0.0002

0.0008

0.78

0.0004

0.0009

0.63

cg22948094

CTNNB1 (64,025)

0.0023

0.0010

0.02

0.0014

0.0012

0.27

− 0.0017

0.0013

0.17

cg12729894

MOB2/CTSD (0)

− 0.0007

0.0005

0.14

− 0.0001

0.0006

0.92

0.0008

0.0006

0.23

cg27640302

TIMM10 (0)

0.0007

0.0006

0.29

0.0004

0.0008

0.62

− 0.0004

0.0008

0.63

cg00574958

CPT1A (0)

0.0013

0.0004

0.005

0.0016

0.0006

0.004

− 0.0020

0.0006

0.0005

cg17058475

CPT1A (0)

0.0012

0.0005

0.02

0.0016

0.0006

0.01

− 0.0021

0.0007

0.001

cg24590708

MYO5C (0)

0.0011

0.0017

0.52

− 0.0003

0.0022

0.88

0.0015

0.0022

0.50

cg11024682

SREBF1 (0)

− 0.0002

0.0006

0.79

− 0.0002

0.0008

0.79

0.0002

0.0008

0.79

cg06500161

ABCG1 (0)

− 0.0007

0.0006

0.27

3.6 × 10–5

0.0008

0.96

0.0013

0.0008

0.10

  1. ROSMAP Religious Orders Study (ROS) and Memory and Aging Project (MAP)
  2. Clinical diagnosis of cognitive status at time of death (6 other dementia, 5 Possible Alzheimer’s dementia (AD), 4 Probable AD, 3 mild cognitive impairment [MCI] and another condition, 2 MCI and no other condition, 1 no cognitive impairment), Braak stage: measure of severity of neurofibrillary tangle pathology (coded 0, I to VI), CERAD score: neuropathologic diagnosis based on estimates of neuritic plaque density (1 definite AD, 2 probable, 3 possible, 4 no AD)
  3. P values in bold and italic passed the multiple-testing significance threshold (P < 0.002)
  4. Linear regression models were used to evaluate association of brain DNA methylation (outcome) with clinical cognitive diagnosis or AD-related indices (N = 707), adjusting for age at death, sex, substudy, self-reported race, batch, and cell type proportions